Open Heart

Sex-disaggregated data in hypertrophic cardiomyopathy: a targeted literature review, meta-analysis and primary cohort study

Objective Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy characterised by pathological left ...

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic ...
Nasdaq

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...

Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc. (Imbria), a clinical-stage company developing innovative therapeutics for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
Nasdaq

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...
Morningstar

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

Data highlighted in a late-breaking featured clinical research presentation at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology SHANGHAI ...
manilatimes

Navigating Life with Hypertrophic Cardiomyopathy

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- (Feature Impact) Living with obstructive or non-obstructive hypertrophic cardiomyopathy (HCM) can affect everyday life, your plans and the people around you.